MENLO PARK, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Thomas Leung as chief financial...

MENLO PARK, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new preclinical data at upcoming...

- Clinical Hold until Additional CMC Information is Reviewed by FDA -- Independent DMC Review of Safety Data from First Cohort of Six Patients with No SAEs or DLTs -- Adverum Plans to Present 24-Week Data from First Cohort of Patients at Scientific Meeting in...

MENLO PARK, Cali., April 01, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Aaron Osborne, MBBS MRCOphth as...

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company’s participation in several upcoming...

Advancing Novel Gene Therapy ADVM-022 for Wet AMD in OPTIC Phase 1 Clinical Trial MENLO PARK, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and...

MENLO PARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will be participating in the upcoming Cowen...

MENLO PARK, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will be participating in the upcoming 8th...

Data demonstrates long-term expression of ADVM-022, an intravitreally delivered gene therapy currently in phase 1 for wet AMD, does not affect retinal morphology in non-human primates Initial long-term preclinical safety data out to 21 months post ADVM-022 injection...

Advancing Novel Gene Therapy ADVM-022 for Wet AMD in OPTIC Phase 1 Clinical Trial MENLO PARK, Calif., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology...